New Publication: Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy
Home
>
Science Hub
>
New Publication:
Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy
April 11, 2024
Hartmut Koeppen et al. The Journal of Pathology
Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy
You might also be interested by
Press Releases
Lunit, CellCarta Announce Global Alliance to Expand Access to Digital Pathology AI for Clinical Trials
September 24, 2025
More infoCellTalk Blog
B-Cell Populations in Focus: A New Flow Cytometry Assay for Increased Sensitivity in Autoimmune Research
September 19, 2025
Flow Cytometry
More infoCellTalk Blog
Next-Gen Immune Monitoring: The Value of Single-Cell Sequencing
August 12, 2025
More info